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Selection of viral mutants resistant to compounds used in therapy is a major determinant of treatment
failure, a problem akin to antibiotic resistance in bacteria. In this scenario, mutagenic base and nucleoside
analogs have entered the picture because they increase the mutation rate of viral populations to levels
incompatible with their survival. This antiviral strategy is termed lethal mutagenesis. It has found a major
impulse with the observation that some antiviral agents, which initially were considered only inhibitors
of virus multiplication, may in effect exert part of their antiviral activity through mutagenesis. Here, we
review the conceptual basis of lethal mutagenesis, the evidence of virus extinction through mutagenic
nucleotide analogs and prospects for application in antiviral designs.
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The prevention and treatment of diseases associated with RNA viruses is based on two major strategies: vaccination
and pharmacological intervention. Both have met with considerable difficulties derived mainly from the still
limited knowledge of the basis of protective responses evoked by vaccines, and underestimation of the capacity of
viral populations to overcome immune responses and inhibitory activities. In the case of antiviral inhibitors, two
main factors intervene: the selection of inhibitor-resistant viral mutants while viruses replicate in the infected host
subjected to treatment, and the increase at the epidemiological level of circulating viruses that harbor resistance
mutations. The basal level of resistance mutations varies greatly among different pathogens, but it may diminish the
efficacy of an initial treatment. The challenge of avoiding escape mutants has been responded to in clinical practice
with a deeper characterization of viral populations prior to treatment onset, and the use of combination therapies
that for statistical reasons render selection of escape mutants a far less frequent event than with monotherapy.
Nevertheless, the problem is far from being solved, and its roots lie in the capacity of RNA virus populations to
respond to changing environments such as the introduction of antiviral inhibitors during their replication.
Because of their being general features of RNA viruses, high mutation rates and the generation of mutant swarms
demand new disease control strategies [1–6]. An approach with a mounting impact in antiviral research consists
in driving viral populations toward nonfunctionality by an increase of the average mutation rate. This strategy is
known as lethal mutagenesis or transition into error catastrophe. Error catastrophe was initially used to describe
deterioration of cellular functions as a hypothesis for the process of aging [7]. Subsequently, it was adopted in
quasispecies theory to refer to a critical transition from organized distribution of genomes (dominated by one or
several ‘master’ sequences) toward a collection of genomes that, devoid of a master sequence, drift in sequence
space. Quasispecies theory was developed by Eigen and Schuster to describe quantitatively genome replication with
production of error copies, as a step in self-organization of simple replicons at the origin of life [8]. Despite different
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views on the mechanism of virus extinction by excess mutations, quasispecies theory was at the inception of the
experiments that opened the way to this new antiviral strategy [5,9,10].
The term lethal mutagenesis was coined by Loeb et al. who documented the adverse effect of the pyrimidine
analog 5-hydroxydeoxycytidine on HIV-1 replication [9]. The introduction of excess mutations in viral genomes
is often achieved with base and nucleoside analogs that display acceptable levels of toxicity for host cells and
organisms. They are intracellularly converted into their active nucleotide forms. The latter can take the place
of standard nucleotides, and be ambiguously incorporated opposite to any of the two complementary purine
or pyrimidine template residues. Once incorporated, they induce misincorporations acting as template residues
during the following replication rounds. Some mutagenic analogs can also produce RNA chain termination,
although compounds whose mechanism of action is limited to RNA chain termination constitute a different group
of antiviral agents [11]. The molecular basis of mutagenesis by nucleotide analogs is only partially understood but
it likely comprises base mispairing through hydrogen bonds that differ in location and strength from those that
dictate the standard Watson-Crick or wobble base pairs.
Lethal mutagenesis is an expanding chapter of antiviral pharmacology due to the impulse of theoretical and
experimental studies, together with the finding that some antiviral inhibitors that were licensed for administration
to humans as inhibitors of viral replication may actually exert their antiviral activity partly through mutagenesis.
The classical example is ribavirin (1-β-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide), a purine analog used
as antiviral agent since the 1970s that displays multiple mechanisms of activity, such as depletion of GTP levels
through inhibition of cellular inosine-monophosphate dehydrogenase by its mononucleotide derivative ribavirin-
monophosphate, enhancement of the antiviral Th1 immune response, inhibition of mRNA cap formation and
direct inhibition of viral RNA-dependent RNA polymerase [12]. Ribavirin was first shown to be mutagenic for
poliovirus [13], and then for several RNA viruses [12]. Ribavirin and other base and nucleoside analogs, some used
in cancer chemotherapy (e.g., 5-fluorouracil or 5-azacytidine), have contributed to the development of lethal
mutagenesis (Table 1).
Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pirazinecarboxamide), another purine analog introduced more recently
as antiviral agent [14], has followed a similar course of events. It was shown to be an inhibitor of influenza virus RNA
replication, with an RNA chain termination activity [15,16], and some key residues of the polymerase of positive-
sense single-stranded RNA viruses identified as determinant of its broad-spectrum antiviral activity [17]. Favipiravir
is approved as an anti-influenza virus agent in Japan. It was later proven mutagenic for influenza virus [18], and then
for several additional RNA viruses in cell culture and in vivo (Table 2). Particularly noteworthy is the evidence that
protective favipiravir doses against Ebola virus infection in macaques were associated with mutagenesis [19].
Many studies with different viruses and mutagenic agents have confirmed that RNA viruses can be extinguished
by increasing their mutation rate during replication, with consistent outcomes with viruses that use different
replication mechanisms (Tables 1 & 2).
Multiple questions & models, but one outcome
As it sometimes happens in science, once lethal mutagenesis was perceived as a potential antiviral strategy, its
conceptual foundations became of interest to experts in widely different disciplines who proposed different inter-
pretations. This did not come as a surprise given its origins in quasispecies theory, connections with population
genetics and implications for antiviral pharmacology, with its commercial connotations. In addition to its molecular
basis, the antiviral activity of nucleotide analogs has raised several questions that are currently under investigation: Is
the mutagenic activity the direct cause of virus extinction? When an analog targets the RNA-dependent RNA poly-
merase (RdRp; not other cellular or viral functions), is the observed viral inhibition a consequence of mutagenesis
or do mutagenic and inhibitory activities coexist independently? Do other base, nucleoside and nucleotide analogs
used in antimicrobial or anticancer therapy have hitherto unrecognized mutagenic activities for RNA viruses? Some
of these issues are discussed next, with an effort to reconcile theoretical proposals with experimental findings.
Extended Darwinian dynamics, which captures processes of mutant generation, competition and selection has
had different mathematical formulations in history. Since the different equations that describe such formulations
are related [20], the question is why was quasispecies the framework adopted to explain RNA virus behavior at
the population level. A convincing reason is that the fundamental equation that describes quasispecies dynamics
quantifies the variation as a function of time of the concentration of individual genomes due to replication rate
and the occurrence of mutations (from and toward any individual genome) (formulation summarized in [8], and
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Table 1. Summary of some studies on lethal mutagenesis of viruses by base and nucleoside analogs.†
Virus Host Drug and concentration range Main observations Ref.
VSV
PV
BHK-21, HeLa cells FU (1–200 g/ml)
5-aza-C (1–10 g/ml)
Impairments of viral replication; 16- to 2.8-fold increases in mutation
frequency
[10]
VSV BHK-21 cells FU (3–400 g/ml) Adverse effect of mutagenesis on virus viability and adaptability [86]
HIV-1 CEM cells 5-OH-dc (1000 M) Decrease of virus infectivity; threefold increase of mutation frequency
and 5.6-fold increase in G→A transitions
[9]
FMDV BHK-21 cells FU (10–1000 g/ml)
5-aza-C (5–10 g/ml)
Decrease of virus infectivity; fitness and viral load-dependent
extinction. 2- to 6.4-fold increase in mutation frequency
[23]
FMDV BHK-21 cells FU (200 g/ml) Virus extinction by FU in combination with the nonmutagenic
inhibitors guanidine hydrochloride and heparin Requirement of drug
combination to extinguish high fitness FMDV
[43]
PV HeLa cells RBV (100–1000 M) 99.3% loss of genome infectivity with 9.7-fold increase in mutagenesis [87]
LCMV BHK-21 cells FU (10–100 g/ml)
5-aza-C (5–10 g/ml)
Virus extinction; largest increases in mutation frequency did not
predict extinction
[57]
FMDV BHK-21 cells RBV (100–500 M) Curing of virus from persistently infected cells, associated with up to
tenfold increase of mutation frequency
[88]
FMDV BHK-21 cells FU (100–200 g/ml) Virus extinction required mutagenesis and not only inhibition by
guanidine hydrochloride and heparin
[26]
LCMV BHK-21 cells FU (50–800 g/ml)
RBV (100–400 M)
FU- and RBV-mediated extinction of LCMV in BHK-21 cells, associated
with up to tenfold increases of mutation frequency with FU and
inhibition of gene expression with RBV
[60]
HTNV Vero E6 cells RBV (12 g/ml) Adverse effect of RBV on HTNV gene expression and progeny
production; 8.7-fold increase of mutation frequency in S-RNA
[89]
WNV HeLa, CV-1, L929, Vero,
MA-104 cells
RBV (100 g/ml) Evidence of RBV-mediated extinction of WNV in HeLa (but not other
cell types) associated with increased mutation frequency and
decreased specific infectivity
[90]





5-aza-dC (10 nM–1 mM) Adverse effect of 5-aza-dC on HIV-1 infectivity, with its principal
mechanism being incorporation during reverse transcription
[91]
FMDV BHK-21 cells FU (200–500 g/ml) Extinction of a RBV-resistant mutant by combination of FU and
guanidine hydrochloride
[92]
LCMV BHK-21 cells RBV (20–100 M) RBV subinhibitory concentrations exerted mutagenic activity through
an increase of mutant spectrum complexity, decrease of specific
infectivity and increase of G→A, C→U transitions
[61]
HIV-1 U373-MAGICXCR4 5-aza-dC (10–200 M) Adverse effect of 5-aza-dC on viral infectivity, potentiated by the host
factor APOBEC3G
[93]
HCV Huh-7.5 cells RBV (50–100 M) RBV-mediated extinction of HCV through an increase of mutant
spectrum complexity and decrease of specific infectivity
[94]
TMV N. tabacum FU (up to 100 g/ml) FU-mediated decrease of TMV infectivity and increase of A→G, U→C
transitions
[30]
†The list of studies is not exhaustive, and the chosen examples are given in chronological order of publication. Only investigations that have addressed adverse effects on virus
replication or have documented virus extinction are included.
5-aza-C: 5-Azacytidine; 5-aza-dC: 5-Aza-2′-deoxycytidine; 5-OH-dC: 5-Hydroxydeoxycytidine; AZT: 3′-Azido-3′-deoxythymidine; FMDV: Foot-and-mouth disease virus; FU: 5′-
Fluorouracil; HCV: Hepatitis C virus; HIV-1: Human immunodeficiency virus type 1; HTNV: Hantaan virus; LCMV: Lymphocytic choriomeningitis virus; PV: Poliovirus; RBV: Ribavirin;
TMV: Tobacco mosaic virus; VSV: Vesicular stomatitis virus; WNV: West Nile virus. All studies were carried out in cell culture except that with TMV which was performed in vivo.
explained in the context of RNA viral evolution in [3]). The parallelism between the processes of mutation and
correct replication distinguishes quasispecies from other Darwinian formulations [20].
The consideration of mutation as inherent to replication underlies the error threshold relationship of quasispecies
theory [21,22] that predicts loss of inheritable information when error rates exceed a threshold value. The error
threshold value is determined by the complexity of the information to be transmitted (equated with genome
size, provided redundant information is absent), and by the degree of adaptation of the replicating ensemble to
the environment (quantified by the fitness superiority of the dominant or master sequence or sequences over the
surrounding mutant spectrum) [8,22]. This general prediction applies to all replicative entities, and, importantly, it
was experimentally verified with RNA viruses, and it is also amenable to investigations with other RNA genetic
elements and DNA viruses or replicons that display high basal average mutation rates. The usual range of mutation
rates in these subcellular entities is 10-3 to 10-5 substitutions per nucleotide [5]. Copying fidelity is restricted by
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Table 2. Summary of some studies on lethal mutagenesis of viruses induced by favipiravir (T-705) or derivates.†
Virus Type of study Host Concentration
range tested
Mutational effect Mutant type preference in
treated populations
Specific infectivity Ref.
IV Cell culture MDCK cells 0.5–16 M ∼3.35-fold increase Bias in favor of G→U and
C→U
∼25-fold decrease [18]
MNV Cell culture RAW264.7 cells 200–800 M Five- to sixfold
increase





MNV In vivo C57BL/6 mice 600 mg/kg per day ∼2.9-fold increase n.s. ∼Tenfold decrease [65]
HCV Cell culture Huh-7.5 cells 100–400 M ∼Two to fivefold
increase










WNV Cell culture Vero cells 0.5–2 mM ∼ 5.6-fold increase Bias in favor of G→A and





DENV Cell culture Huh-7 cells 200–500 M ∼Two- to 33-fold
increase
Bias in favor of transitions ∼Sevenfold
decrease
[64]










ZIKV Cell culture Vero cells 100–800 M ∼Fourfold increase Bias in favor of G→A and
C→U
∼30-fold decrease [97]
IV Cell culture MDCK, 293T cells 1–100 M ∼Two- to 13-fold
increase
Bias in favor of G→A and
C→U
n.s. [98]
†The list of studies is not exhaustive, and the chosen examples are given in chronological order of publication. Only investigations that have addressed adverse effects on virus
replication or have documented virus extinction are included.
DENV: Dengue virus; EBV: Ebola virus; FMDV: Foot-and-mouth disease virus; HCV: Hepatitis C virus; IV: Influenza virus; MNV: Murine norovirus; n.s.: Not specified.; WNV: West
Nile virus; ZIKV: Zika virus.
the absence of proofreading-repair activities, and poor activity of additional cellular repair functions during RNA
replication and retrotranscription. The experiments that originated lethal mutagenesis as we understand it today
were designed to explore the prediction of the error threshold relationship regarding the adverse effects of increasing
the mutation rate on virus genetic and functional stability [9,10,23] (Figure 1). The results agreed with the prediction,
and replication of RNA viruses was hampered by high mutation rates, and in several cases virus extinction was
achieved (Table 1).
Some alternative models to the crossing of the error threshold for maintenance of inheritable information implied
by quasispecies theory were proposed to explain virus extinction by artificially enhanced mutation rates (reviewed
in [24]). Eventually, extinction of a microbial pathogen is always a demographic process in which the infection cannot
be sustained [25]. The critical issue is what triggers the demographic event. At least with the picornavirus foot-and-
mouth disease virus (FMDV) under our cell culture conditions, mutagenesis was essential for loss of infectivity
since equivalent inhibitory intensities achieved with nonmutagenic inhibitors did not result in virus extinction [26].
Additional studies (reviewed in [5]) suggest that a mutagenesis-driven movement of the virus population toward
unfavorable regions of sequence space, in which defective genomes increase in frequency, may be key to virus
extinction. This proposal is based on experimental results, together with theoretical studies performed by Manrubia
and colleagues (several of them reviewed in [3,5]). Two steps were identified in the process of extinction that suggested
a complex transition at the molecular level. In the first step, the mutant cloud distribution produced under the basal
mutagenesis input typical of RNA viruses is first perturbed by enhanced mutagenesis, due to generation of defective
genomes that interfere with replication of standard (still nonmutagenized or minimally mutagenized, nondefective)
genomes. In our systems, this interference that we call lethal defection, by itself impeded progression of the infection,
and led to virus extinction [27]. The occurrence of a lethal defection phase was experimentally supported by the fact
that loss of infectivity preceded elimination of viral RNA [27], and by the presence in mutagenized viral populations
of mutants that exerted an interfering activity [28,29]. The model has found also support in the antiviral activity of
5-fluorouracil (FU) on the plant virus tobacco mosaic virus [30], a study that has inaugurated lethal mutagenesis
for plant viruses. It is interesting that a participation of defective genomes in virus extinction adds to evidence of
the role of several classes of defective genomes, including defective-interfering particles, in various aspects of virus
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Figure 1. Flow of concepts from the error threshold relationship of quasispecies theory to lethal mutagenesis, and
related issues. Justification and references are given in the text.
biology (innate immune responses, modulation of replication and virulence, and viral persistence [31,32]), a true
revival of implications put forward half a century ago [33,34].
The second step is reached as mutagenesis proceeds beyond the lethal defection phase and mutations accumulate,
due either to mutagenesis sustained in time or higher mutagen doses per unit time. This new stage has been termed
overt lethality, and it is characterized by a larger average number of mutations per genome. Its expected occurrence,
given the average deleterious effects of multiple random mutations in the same genome, was further supported by
the rescue during FMDV mutagenesis of genomes that could not be viable due to critical polymerase lesions, as
evidenced by biochemical and structural investigations [35]. If high mutagenic rates are reached directly, the lethal
defection phase is expected to be brief or absent, and extinction to be a direct consequence of overt lethality. In the
standard cell culture and in vivo scenarios, lethal defection and overt lethality probably overlap during the transition
toward extinction, as suggested by isolation from FMDV on its way toward extinction of infectious biological
clones that display a wide range of fitness values [36]. Given the mutant spectrum complexity of mutagenized viral
populations, it is possible that additional categories of viral variants and types of intergenome interactions still to
be discovered, intervene in the process of extinction. Deterioration of viral functions due to mutations is expected
to occur at the RNA and protein levels, and viral protein stability may be a relevant factor [37–39].
The lethal defection-overt lethality model is not incompatible with the theoretical proposal that the loss of the
master sequence generates a drifting mutant cloud that due to the advantage of genomes lying on a high fitness
plateau (termed advantage of the flattest) [40,41] should not reach extinction (reviewed in [24]). From what we know
of the molecular biology of RNA viruses, a drift in sequence space (without guiding selection), which from a
theoretical point of view should perpetuate the mutant spectrum, would in reality provoke that genomes soon
reach points of nonviability. The various theoretical arguments have had the merit of emphasizing an important
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distinction: loss of superiority of the master sequence and survival of a drifting mutant spectrum (that fits the
error threshold concept of quasispecies theory) versus extinction of both the master sequence and the mutant
spectrum (that fits extinction of viruses) [42]. The aim of lethal mutagenesis is extinction of both the master or
dominant sequences and their surrounding mutant spectra, although the loss of master superiority by itself may be
a predisposing factor to reach extinction.
Deep sequencing methodologies (that count as tens of thousands the number of genomes that can be sequenced
from a viral population) have dispelled any doubts about the extreme complexity of mutant spectra of RNA viruses.
Deep sequencing characterization of mutagenized RNA viruses (a type of analysis which is still in its infancy),
may help elucidate the contribution of different molecular events to extinction. Despite alternative theoretical
preferences, the end result is that enhanced mutagenesis, which is within reach of current pharmacology, can
achieve virus extinction, and that its molecular basis is neatly distinct from that of standard inhibition of virus
replication. To further address this important issue, next we briefly review studies to illustrate parameters that affect
the efficacy of lethal mutagenesis, with emphasis on proofs of concept.
Critical findings & current research
Initial work with FMDV indicated that high viral fitness and large viral population size decreased the efficacy of
mutagenic agents, and delayed virus extinction, in agreement with the prediction of the error threshold relation-
ship [23]. For high fitness FMDV and HIV-1 populations, it was necessary to combine a mutagenic agent with a
nonmutagenic inhibitor to achieve extinction [43,44].
A higher suppresive effect of a sequential administration of an antiviral nonmutagenic inhibitor, followed by a
mutagenic agent than the converse (first a mutagenic agent and then an inhibitor) or the corresponding combination
(inhibitor and mutagen-administered together) was documented with FMDV and lymphocytic choriomeningitis
virus (LCMV) as model systems in cell culture. For FMDV, the advantage was shown using guanidine hydrochloride
as inhibitor and FU as mutagen [45]. For LCMV, similar conclusions were reached with FU and ribavirin at
concetrations at which it acts mainly as mutagen or as inhibitor [46].
The results of a preferred sequential inhibitor-mutagen administration to supress viral replication are consistent
with a theoretical model of the interplay between mutagenic agents and inhibitors acting on a replicating virus,
and also with the fact that absence of an inhibitor during the mutagenesis step may permit defective genomes to
contribute to extinction by lethal defection [45]. These findings imply that there is still room to investigate alternative
ways to administer mutagenic agents and nonmutagenic inhibitors for optimal efficacy, and this research is now
in progress. In particular, no data are available in vivo. The accumulating evidence that lethal mutagenesis can be
effective in plants and animals (examples in Tables 1 & 2) opens the way to studies on the efficacy of sequential
versus combined administration of inhibitors and mutagens at the organism level.
Enhancement of drug resistance by high viral fitness has been recently reported with hepatitis C virus (HCV).
Deep sequencing and genetic analyses documented that this class of drug resistance is distinct from the standard
resistance profusely documented with many viruses, since it is independent of the presence of genomes harboring
bonafide-resistance mutations [47,48]. The deep sequencing evidence for this fitness-dependent drug resistance was
that no previously recognized resistance-associated mutations were detected in high fitness HCV populations, at
least within the portion of the mutant clouds observable with current methodology. The genetic evidence was that
similar levels of resistance were scored in infections over a 1000-fold range of multiplicity of infection, as well as in
infections with biological clones isolated from the resistant populations [47,48].
To interpret fitness-dependent drug resistance, it should be emphasized that fitness is a multifactorial parameter
that has proven relevant for RNA virus–host interactions and disease processes [49–52]. The fact that high HCV fitness
decreased sensitivity to all antiviral agents tested (that included mutagenic and nonmutagenic inhibitors, the latter
directed to viral or cellular functions), lent to the proposal of a replicative site-drug competition model to account for
the results [48]. Since fitness increase of HCV was associated with both higher replication rate and higher maximum
level of progeny production [53], we suggested that a larger number of replicative site equivalents in relation to a
given level of drug concentration that reaches the replication complexes, should facilitate drug escape. Support for
this proposal has been recently obtained with the comparison of mutant spectrum complexity and composition
of low and high fitness HCV populations subjected to favipiravir and ribavirin mutagenesis [54]. High fitness did
not modify the mutational bias in favor of G→A and C→U transitions produced by favipiravir or ribavirin on
HCV (other examples of mutational bias are included in Tables 1 & 2), but it limited the expansion of the mutant
spectrum evoked by the mutagenic analogs. The fitness-dependent HCV response to mutagenesis is consistent
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with the replicative site-drug competition mechanism, although other, nonmutually exclusive mechanisms may
also participate [54]. The results with HCV have introduced fitness as a major parameter in the response of viruses
to lethal mutagenesis [54]. A derivation of the mutant spectrum analyses of HCV subjected to mutagenesis has been
the recognition that not all parameters available to quantify the diversity of a mutant spectrum [55] are equally
suited to identify and characterize a process of lethal mutagenesis. Rare haplotype load (the combination of different
mutations in the same read, found at the lowest frequencies) has proven one of the most adequate parameters that
should find an application to distinguish nucleotide analogs that act only as inhibitors from those that display a
mutagenic activity [56].
Work with the arenavirus LCMV provided support for lethal mutagenesis in negative strand RNA viruses [57–59].
A proof of concept obtained with this virus was the demonstration that FU could prevent the establishment of a
persistent LCMV infection in mice [60]. The experiments showed that the administration of a base analog could
limit the progression of a viral infection in vivo. Work with LCMV indicated also a mutagenic activity of ribavirin
for this important group of viral pathogens [61], and supported the possibility of sequential inhibitor-mutagen
administrations for higher antiviral efficacy [46].
A pioneer clinical trial based on a lethal mutagenesis strategy involved administration of the pyrimidine analog
KP-1461 (N4-heptyloxycarbonyl-5,6-dihydro-5-aza-2′-deoxycitidine), the prodrug of KP-1212 (5,6-dihydro-5-
aza-2′-deoxycitidine) to HIV-1-infected patients that at the time did not have other therapeutic possibilities.
Although no HIV-1 extinction was achieved, the virus was mutagenized, thus documenting feasibility of lethal
mutagenesis for human therapy [62]. HIV-1 and retroviruses in general are not the easiest infections to combat with
mutagenic nucleotides since during the proviral step inherent to their replication cycle, the viral genetic material
behaves as part of the host DNA, with the corresponding high template copying fidelity. Current efforts with new
mutagenic agents [63,64], together with strategies to activate proviral DNA expression, may open possibilities of
lethal mutagenesis approaches for retroviruses.
Recent salient in vivo studies with favipiravir (by Arias et al. with norovirus [65], and de Lamballerie and colleagues
with Ebola virus [19], details in Table 2) have reinforced lethal mutagenesis as an antiviral design. These studies with
favipiravir have followed others with ribavirin as a broad-spectrum antiviral agent, in particular as a component
of the treatment for chronic HCV infection. There is a remarkable long-lasting controversy on whether ribavirin
acts as a mutagen for HCV in vivo. Despite clinical evidence of mutagenesis during ribavirin monotherapy [66],
and supportive phylogenetic evidence [67], the dominant mechanism of ribavirin efficacy for HCV is still an open
question. The issue might be resolved soon given the benefits of including ribavirin in some new combinations of
direct-acting antiviral agents, and the increasing application of deep sequencing to the characterization of HCV
populations from infected patients treated with ribavirin-containing inhibitor combinations. Ultradeep sequencing
has recently revealed mutagenesis of the new emergent hepatitis E virus by ribavirin in vivo [68]. A boost for the lethal
mutagenesis field is that ribavirin, one of the most significant inhibitors in the history of antiviral pharmacology [11],
may embrace mutagenesis as an ingredient of its antiviral activity.
Some key features of lethal mutagenesis
Comparison of the mutant spectra of viral populations that have multiplied in absence or presence of nucleotide
analogs has suggested some features of lethal mutagenesis that can serve both to diagnose its occurrence and to
inform of its molecular basis. We have identified the following: A mutagenic analog tends to enhance the mutant
spectrum complexity associated with the transition toward extinction, as evidenced by molecular cloning-Sanger
sequencing and deep sequencing. The increase of mutant-spectrum complexity is often (perhaps not always)
accompanied of a mutational bias which tends to be typical for a given analog, but that may vary depending
on the virus–host system. Documented examples are a predominance of A→G and U→C transitions evoked by
FU, and of G→A and C→U transitions evoked by favipiravir and ribavirin. Mutational spectrum biases are to
be regarded only as tendencies because exceptions have been reported. As examples, favipiravir evoked a slight
increase of A→G and U→C transitions in norovirus RNA [65]. Also, within the mutation detection limits imposed
by molecular cloning-Sanger sequencing, no significant mutational bias was observed in preextinction FMDV
populations passaged in the presence of favipiravir [69]. Statistical reinforcement provided by deep sequencing may
help clarifying the extent of mutational bias evoked by different analogs, and its role in virus extinction. The
transition toward extinction takes place with a significant decrease of specific infectivity (the ratio between the
number of infectious units and the amount of viral RNA at a given time point) and without modification of the
consensus sequence of the population [70,71].
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Table 3. Main features of lethal mutagenesis of viruses.†
• Increase of population diversity, with rare haplotype load as a diagnostic index
• Frequent mutagen-induced mutational bias, dependent on the analog and the virus–host system
• Decrease of virus-specific infectivity, the ratio between the number of infectious units and the amount of viral RNA
• Invariance of the consensus genomic sequence
†Points based on several investigations some of which are reviewed in the text and in Tables 1 & 2.
Thus, the state of the art of lethal mutagenesis has already suggested some generalizations (Table 3) that should
help diagnose this mechanism of viral extinction, and distinguish it from extinction mediated solely by inhibition,
in absence of mutagenesis.
Conclusion: additional comments, challenges & prospects
The fact that lethal mutagenesis is on the way toward a therapeutic reality has come as a surprise mainly to classical
pharmacology that did not count on quasispecies and its conceptual derivations as penetrating this field of medical
research. Several base and nucleoside analogs once considered only inhibitors of viral replication through various
biochemical and immunological mechanisms that did not imply mutagenesis, are now known to be mutagenic
for several RNA viruses. Expanding on some of the issues listed in the Introduction of this article, of particular
interest is a clarification of the actual contribution of the mutagenic activity per se to the antiviral efficacy. For most
nucleotide analogs, mutagenesis is accompanied with other antiviral mechanisms, as amply documented in the case
of ribavirin, and more recently also for favipiravir. To eliminate an array of mechanisms and potential off-target
effects, and to keep mutagenesis of viral RNA as the only mode of action of a drug is not technically feasible. A
related point is that a mutagenic activity should entail an inhibitory activity because of the deterioration of viral
functions induced by mutagenesis. However, there might be an inhibitory activity distinct from the mutagenic
activity. This is the case of ribavirin nucleotides on the HCV polymerase [72], or of FU on FMDV replication [73].
FU-monophosphate binds covalently to primer protein VPg and blocks the protein-directed initiation of RNA
synthesis while the triphosphate form is incorporated during RNA elongation, thereby introducing mutations that
should also result in inhibition. Thus, a current challenge is to quantify the weight of mutagenesis in the extinction
process.
In view of the increasing number of viruses for which favipiravir and ribavirin have proven mutagenic, a pendent
question is whether in viruses for which these analogs have been reported to be inhibitory and not mutagenic,
a mutagenic activity might have been missed. Such a failure could be due to insufficient penetration into the
composition of the mutant spectra, or to the time postinfection or post-treatment chosen for the analysis. When
FMDV was subjected to ribavirin mutagenesis, a transient expansion was followed by a compression of the mutant
spectrum [74,75]. In HCV-infected patients treated with ribavirin, early or transient increases of mutation frequency
have been reported [76,77]. Also, model studies in cell culture [54] suggest that mutant spectrum expansions may be
limited for high fitness HCV, expected to be reached when the virus has undergone long-term adaptation to a human
liver. To complicate matters further, the possible participation of cellular editing activities in viral mutagenesis [78],
and the recognition of cell-coded antiviral ribonucleotides [79] enter the picture of lethal mutagenesis.
A potential problem to be considered is the selection of viral mutants displaying resistance to mutagenic
nucleotide analogs that could jeopardize lethal mutagenesis efficacy. Resistance to mutagenic nucleotide analogs
has been described, but the available data do not allow to conclude whether their frequency is as high as for
standard nonmutagenic inhibitors or not. When resistance to mutagenic nucleotide analogs maps in the viral
polymerase or nonstructural contact proteins it may be due to decrease of affinity for the nucleotide analog or
to modulation of mutation types ([80] and references therein). Selection of nucleotide analog-resistant mutants
has required serial passages under subinhibitory and sublethal concentrations of the mutagenic agent, and have
not been reported during lethal mutagenesis experiments conductive to viral extinction. It is unlikey that escape
mutants can be selected under uninterrupted, enhanced mutagenic activity. However, limitation of the mutagenic
activity in vivo may occur as a result of virus compartmentalization into tissues or organs with limited access to the
nucleotide analogs. Therefore, in vivo evaluations are necessary to monitor mutagen concentrations in the different
compartments where viral replication takes place. As with standard antimicrobial treatments, lethal mutagenesis
must follow the dictum ‘hit early, hit hard’ [81,82].
A relevant issue is the validation of a mutagenic compound as an antiviral agent by regulatory agencies such as
the US FDA. Ribavirin was the FDA approved for the treatment of HCV infection and respiratory syncytial virus
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infection in children, and it is used off-label against some other viral pathogens, notably arenaviruses. Favipiravir
has been licensed as an anti-influenza agent in Japan, and it has been subjected to trials against influenza infections
(US NIH, identifier NCT02008344) and Ebola infections (JIKI trial, US National Institutes of Health, identifier
NCT02662855). It is used off-label against several viral infections. These trials were performed (and licensing
decisions taken) without knowledge of their mutagenic activity for RNA viruses. Further acceptance by the FDA
(and other agencies) for a more extended usage as antiviral agents, not only off-label for life-threatening infections,
would require further evaluations such as by the FDA Center for Drug Evaluation and Research. Although Phase
I (Discovery and Development) have been largely completed for compounds used off-label, aspects of Phase II
(Preclinical Trials), Phase III (Clinical Research), Phase IV (FDA Review) and Phase V (FDA Post-Market Safety
Monitoring) may require evaluation. Accelerated approval may be justified for life-threatening infections without
alternative treatment options (see https//www.fda.gov and https://www.fda.gov/Drugs/DevelopmentApprovalP
rocess/def ault.htm#Developing). New expected developments are: Introduction of new compounds (nucleotide
analogs and other) in lethal mutagenesis protocols, either as a result of drug repositioning or synthesis of new
compounds. This is an active field of research [83], expected to broaden the range of candidate molecules to be
considered for lethal mutagenesis-based antiviral protocols. Additional in vivo experiments with animals and plants
to explore the efficacy of lethal mutagenesis for relevant viral pathogens. Pharmacokinetic evaluations of mutagenic
agents in vivo with quantifications of prodrug and active drug at relevant subcellular localizations. Relaunching of
clinical trials with humans, involving administration of compounds of proven safety and efficacy in animal models;
implementation of treatments in cases of life-threatening viral infections. Extensions to cellular systems such as
cancer for which an error catastrophe concept has been defined [84,85]. If progress in these four points could be
attained during the coming decade, with the support of theoretical models and simulation studies, a new antiviral
strategy derived from the theoretical concept of quasispecies would be on its way to implementation.
Future perspective
It is likely that additional antiviral compounds are proven mutagenic for RNA viruses, thus redefining the mechanism
of activity of some classic and newly developed antiviral agents. This will force reevaluation of side effects in terms
of possible mutagenic activities for host cells and organisms. Until safety issues are cleared from this perspective, use
of lethal mutagens may be restricted to life-threatening infections for which no alternative, effective nonmutagenic
inhibitors are available. These developments should parallel basic research to optimize administration protocols in
vivo to minimize dosage and maximize efficacy.
Executive summary
• Lethal mutagenesis is an active and growing field of antiviral research.
• Two major steps have been identified in the process of lethal mutagenesis: lethal defection or interference by
newly generated mutants, and overt lethality due to accumulation of mutations.
• Important antiviral agents such as ribavirin and favipiravir, once considered only inhibitors, may actually exert
their antiviral activity partly as mutagenic agents.
• Viral fitness can be a determinant of resistance to lethal mutagenesis, as evidenced by work with hepatitis C virus.
• Sequential inhibitor-mutagenic administrations may be more effective than the corresponding combinations, and
substantiation of this finding in cell culture requires in vivo evaluations.
• Extensions to anticancer therapy are among several developments that can be anticipated in this rising field of
investigation.
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51. Quiñones-Mateu ME, Arts E. Virus fitness: concept, qunatification, and application to HIV population dynamics. Curr. Top. Microbiol.
Immunol. 299, 83–140 (2006).
52. Wargo AR, Kurath G. Viral fitness: definitions, measurement, and current insights. Curr. Opin. Virol. 2(5), 538–545 (2012).
53. Moreno E, Gallego I, Gregori J et al. Internal disequilibria and phenotypic diversification during replication of hepatitis C virus in a
noncoevolving cellular environment. J. Virol. 91, e02505-16 (2017).
54. Gallego I, Gregori J, Soria ME et al. Resistance of high fitness hepatitis C virus to lethal mutagenesis. Virology 523, 100–109 (2018).
future science group www.future-science.com 1655
Review Perales, Gallego, de Ávila et al.
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